| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
Osimertinib (AZD9291) (0-10 μM; 72 hours) has IC50s of 41, 26, 41, and 31 nM, respectively, which significantly inhibit cell proliferation[2]. With IC50s of 6, 7, and 74 nM, respectively, osimertinib (0-10 μM; 72 hours) inhibits the proliferation of Ba/F3 cells harboring a T790M mutation, exon 19del+T790M, or L858R+T790M. Ba/F3 cells with EGFR exon 20 insertion mutations are inhibited by osimertinib (0-10 μM; 72 hours); the IC50 ranges from 16-701 nM for A763_Y764insFQEA (FQEA), Y764_V765insHH (HH), A767_V769dupASV (ASV), and D770_N771insNPG (NPG) cells [2]. In sensitizing-mutant (mean IC50 of 8 nM in PC-9) and T790M (mean IC50 of 11 and 40 nM in H1975 and PC-9VanR, respectively) EGFR cell lines, osimertinib exhibits high levels of phenotypic potency. Compared to wild-type EGFR, osimertinib exhibits significantly less activity (mean IC50 of 650 and 461 nM in Calu3 and H2073, respectively)[1]. Ba/F3 cells are exposed to 0.1 μM of osimertinib for 48 hours, which causes apoptosis (rates of 40.9% and 90%, respectively, for EGFR exon 19del+T790M and EGFR L858R+T790M) [2].
|
|---|---|
| ln Vivo |
Both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models exhibit significant dose-dependent regression when oximertinib (0.1–25 mg/kg; po; daily for 14 days) is administered[1].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: PC-9, H3255, PC-9ER, and H1975 cells Tested Concentrations: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Dramatically inhibited cell proliferation (IC50=41,26, 41, 31 nM, respectively) Cell Proliferation Assay[2] Cell Types: Ba/F3 cells (harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) Tested Concentrations: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited cell proliferation (IC50 = 6, 7, 74 nM, respectively) Apoptosis Analysis[2] Cell Types: Ba/F3 cells (harboring EGFR exon 20 insertion mutations) Tested Concentrations: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited cell proliferation (IC50 = 16, 701, 230, 38 nM, respectively) Apoptosis Analysis[2] Cell Types: Ba/F3 cells (harboring EGFR exon 19del+T790M or EGFR L858R+T790M) Tested Concentrations: 0.1 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inducted apoptosis with the rate of 40.9% and 90% in EGFR T790M positive mutations cells respecti |
| Animal Protocol |
Animal/Disease Models: PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models[1]
Doses: 0.1-10 mg/kg (PC-9 xenograft models); 0.5- 25 mg/kg (H1975 xenograft models) Route of Administration: po; daily for 14 day Experimental Results: Induced significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models. |
| References |
|
| Molecular Formula |
C28H33N7O2
|
|---|---|
| Molecular Weight |
505.6443
|
| Exact Mass |
505.307
|
| CAS # |
1638281-44-3
|
| Related CAS # |
Osimertinib;1421373-65-0;Osimertinib mesylate;1421373-66-1
|
| PubChem CID |
87056174
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
37
|
| Complexity |
752
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C(C([H])=C(C(=C1[H])N(C([H])([H])[H])C([H])([H])C([H])([H])N(C([2H])([2H])[2H])C([2H])([2H])[2H])N([H])C(C([H])=C([H])[H])=O)N([H])C1=NC([H])=C([H])C(C2=C([H])N(C([H])([H])[H])C3=C([H])C([H])=C([H])C([H])=C32)=N1
|
| InChi Key |
DUYJMQONPNNFPI-XERRXZQWSA-N
|
| InChi Code |
InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i2D3,3D3
|
| Chemical Name |
N-[2-[2-[bis(trideuteriomethyl)amino]ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9777 mL | 9.8885 mL | 19.7769 mL | |
| 5 mM | 0.3955 mL | 1.9777 mL | 3.9554 mL | |
| 10 mM | 0.1978 mL | 0.9888 mL | 1.9777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
